New therapeutic vax targets multiple cancers

Investigators are reporting promising results from their early-stage trial of a new therapeutic cancer vaccine. Scientists say the new vaccine uses an alphavirus to deliver a gene for the carcinoembryonic antigen. Alphaviruses are known to naturally track down dendritic cells, a powerful stimulator of the immune system. In a small human trial involving 28 participants suffering from a variety of late-stage cancers, the vaccine was able to help five of the patients. Story

Suggested Articles

Novavax has inked a $60 million contract with the U.S. Department of Defense to help fund U.S.-based manufacturing of its COVID-19 vaccine candidate.

Since the Warp Speed selections went public, experts have been wondering why some drugmakers were left off.

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.